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Abstract: Hypothesis: Anti-diabetic drugs modulate p-21 activated kinase (PAK) signaling.
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic inflammatory disease associated with
increased cancer risk. PAK signaling is implicated in cellular homeostasis when regulated, and cancer
when unrestrained. Recent reports provided a role for PAK signaling in glucose homeostasis, but the
role of PAKs in the pathogenesis of T2DM is unknown. Here, we performed a mini-meta-analysis
to explore if anti-diabetic drugs modify PAK signaling pathways, and provide insight regarding
modulation of these pathways, to potentially reduce diabetes-associated cancer risk. Methods: PAK
interacting partners in T2DM were identified using the online STRING database. Correlation studies
were performed via systematic literature review to understand the effect of anti-diabetic drugs on PAK
signaling. A mini-meta-analysis correlated multiple clinical studies and revealed the overall clinical
response rate and percentage of adverse events in piogliazone (n = 53) and metformin (n = 91) treated
patients with PAK-associated diseases. Results: A total of 30 PAK interacting partners were identified
(10: reduced beta-cell mass; 10: beta-cell dysfunction; 10: obesity-insulin resistance), which were
highly associated with Wnt, and G-protein signaling. The anti-diabetic drug metformin activated
signaling pathways upstream; whereas pioglitazone inhibited pathways downstream of PAK. Overall,
clinical response upon pioglitazone treatment was 53%. Seventy-nine percent of pioglitazone and 75%
of metformin treated patients had adverse events. Pioglitazone reduced molecular-PAK biomarkers
of proliferation (Ki67 and CyclinD1), and metformin had the opposite effect. Conclusions: PAK
signaling in T2DM likely involves Wnt and G-protein signaling, which may be altered by the
anti-diabetic drugs metformin and pioglitazone. Apart from the therapeutic limitations of adverse
events, pioglitazone may be promising in chemoprevention. However long-term multi-centered
studies, which initiate pioglitazone treatment early will be required to fully assess the full potential
of these drugs.
Keywords: p-21 activated kinase; pioglitazone; metformin; type 2 diabetes mellitus; cancer;
chemoprevention; inflammation
1. Introduction
Type 2-diabetes mellitus (T2DM) is a global epidemic that significantly reduces the quality of life
of geriatric patients, especially in Western society. The etiology of T2DM is intimately linked to obesity,
genetics, and a sedentary lifestyle. Disease manifestations, including blindness and neuropathy, are
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extremely burdensome, and long-term complications such as cardiovascular disease and renal failure,
ultimately result in death [1].
Although the pathogenesis of T2DM is multifactorial and complex, its current understanding
encompasses hepatic insulin resistance, dysfunctional insulin signaling, abnormal glucose metabolism,
and persistent hyperglycemia [1]. In addition to disease specific complications, several consequences
of hyperglycemia have been described, such as an aberrant immune response, chronic inflammation,
and tumorigenesis [2]. Cancer is increasingly common in the elderly, but persistent diabetes also
increases the lifelong risk of developing pancreatic, liver, and colorectal cancers and also fuels the
tumor microenvironment in cancer patients [2].
Anti-diabetic drugs such as biguanides, sulfonylureas, and glitazones have provided the current
basis of understanding in the clinical management of T2DM. However, little is known regarding
whether these drugs are also effective in reducing the associated cancer risk. Effective chemoprevention
in T2DM will target processes involved in both glucose metabolism and carcinogenesis.
Molecular targets with emerging roles in both cancer and diabetes include a family of six different
kinases, the p-21 activated kinases (PAKs) [3]. Here, we reviewed the literature to further understand
PAK signaling in T2DM. We aimed to correlate the potential effects of anti-diabetic drugs on PAK
signaling in order to provide insight on utilizing PAK signaling as a molecular target in cancer
chemoprevention in diabetic patients.
2. Methods
2.1. Molecular Analysis of PAK Signaling Pathways and Their Involvement in Response to Anti-Diabetic
Drugs
A systematic literature review and molecular analysis of pre-clinical studies using online
library Pubmed (https://www.ncbi.nlm.nih.gov/pubmed) was performed to establish upstream
and downstream PAK targets. Key words included PAK signaling or p-21 activated kinases in addition
to the following targets: AMPK, RAS, mTOR, PI3K/AKT, RAC1, CDC42, MAPK, p38, JNK, NF-κB,
PPARγ, ROS, VEGF, and Wnt/Beta-catenin. Similar studies were screened for PAK signaling pathways
involving known targets (above) of glucose homeostasis, inflammation, proliferation, survival, and
angiogenesis. Both upstream and downstream PAK targets were identified in each of these pathways,
and the effect of PAK signaling targets on inflammation, proliferation, survival, and angiogenesis was
evaluated. Studies in the literature involving anti-diabetics drugs (glitazones, metformin, glyburide)
were further analyzed for their effect on PAK signaling pathways (inflammation, proliferation, survival,
angiogenesis) on targets upstream and downstream of PAKs.
2.2. Identification of PAK Interacting Partners
PAK interacting partners were identified using the STRING database as seen in [4,5]. Confidence
was set to 0.40 and active prediction methods, neighborhood, gene fusion, co-occurrence, co-expression,
experiments, database, and text mining analysis were performed. Interacting partners were identified
in three different conditions which may predispose to T2DM using targets of reduced beta-cell
mass (CDKAL1, CDKN2A, CDKN2B), beta cell dysfunction (MTNR1B, TCF7L2, KCNJ11), and
obesity/insulin resistance (FTO, IRS1, PPARγ), as reported [1]. Novel PAK interacting partners
were further investigated and their pathophysiological role in T2DM was investigated and references
for further exploration of targets were provided. All PAK partners were analyzed according to the
molecular pathway involved in T2DM.
2.3. Clinical Study Inclusion/Exclusion Criteria and Mini-Meta-Analysis
Human clinical studies were identified on ClinicalTrial.gov. Inclusion criteria consisted of
observational or interventional studies using metformin or pioglitazone in patients with diseases
previously identified in the literature to have increased PAK expression levels such as bladder,
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leukoplakia, lung, prostate, esophageal, and colorectal cancer [3]. Studies with molecular biomarker
analysis or targets downstream of PAKs were included. Studies without data were excluded from
analysis. Clinical analyses of overall response rate, adverse events, as well as molecular analysis
of biomarkers were performed on pooled data from pioglitazone or metformin treated patients.
Observations were analyzed using statistical analysis of variance (ANOVA) and Tukey HSD post
hoc tests set at 95% confidence intervals. Calculations were performed using the online tool located
at http://statpages.info/anova1sm.html. Chi-squared and independent sample Student’s t-tests
were performed using the online calculator located at www.socscistatistics.com. Significant p values
were <0.05.
3. Results
3.1. PAK Signaling Is Associated with Diabetes and Cancer
Previous studies have provided a role for PAK in both diabetes and cancer, however a clear
overview of the signaling pathways involved in both diseases has not been performed. Systematic
review of the literature correlated 14 signaling pathways, which were identified as crucial to PAK, either
upstream or downstream of PAK, and 11 or 78% of these pathways were also associated with glucose
homeostasis (Tables 1 and 2; Supplementary Figures S1 and S2). All of the PAK signaling pathways
which were associated with glucose homeostasis were also associated with malignant inflammatory,
proliferative, survival, and angiogenic signaling, which occurs in diseases such as cancer (Table 3 and
Supplementary Figure S3).
Table 1. Upstream and downstream PAK signaling pathways. Upstream (left) pathways result in PAK
activation. Activated PAK contributes to multiple downstream signaling pathways (right).
Upstream Downstream
AMPK [6] MAPK-p38/JNK [7]
RAS [8] MAPK-ERK [9]
mTOR [10,11] mTOR [12]
PI3k/AKT [13] PI3k/AKT [9,12,14]
RAC1 [15] NF-kB [14]
CDC42 [15] p-PAK1 [14]
PPARy [14]
ROS [16]
VEGF [9]
Wnt/B-catenin [17–19]
Table 2. PAK signaling pathways are involved in glucose homeostasis. The role of PAK in glucose
homeostasis is complex. Each PAK signaling pathway plays a unique part in glucose homeostasis, and
significant overlap exists between each of the pathways listed.
PAK Signaling Pathways in Glucose Homeostasis
Reference
AMPK [6,20]
MAPK-p38/JNK [21]
MAPK-ERK [22]
mTOR [23]
NF-kB [24]
p-PAK1 [25]
PI3K/AKT [26]
PPARy [27]
RAC1/CDC42 [28,29]
RAS [30]
Wnt/Beta-catenin [31]
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Table 3. Role of PAK signaling in disease. PAK activation or overexpression in malignant disease
results in activation of multiple signaling pathways, which drive inflammation, proliferation, survival,
and angiogenesis. Arrows indicate the effect of signaling pathways on inflammation, proliferation,
survival, and angiogenesis.
Role of PAK Signaling Pathways in Disease
Pathway Inflammation Proliferation Survival Angiogenesis Reference
AMPK ↓ ↓ ↑ ↑ [32–35]
MAPK-p38/JNK ↑ ↑ ↑ ↑ [36]
MAPK-ERK ↑ ↑ ↑ ↑ [9]
mTOR ↑ ↑ ↑ ↑ [37]
NF-kB ↑ ↑ ↑ ↑ [14]
p-PAK1 ↑ ↑ ↑ ↑ [38]
PI3k/AKT ↑ ↑ ↑ ↑ [37]
PPARy ↓ ↓ ↓ ↑↓ [39,40]
RAC1/CDC42 ↑ ↑ ↑ ↑ [15,18,26,28]
ROS ↑ ↑↓ ↑↓ ↑↓ [16,41]
VEGF ↑ ↑ ↑ ↑ [42,43]
Wnt/B-catenin ↑ ↑ ↑ ↑ [17–19,38]
3.2. PAK Interacting Partners Are Associated with the Pathogenesis of T2DM
The pathogenesis of T2DM was previously linked to obesity, insulin resistance, and molecular
alterations of pancreatic beta cells [1]. PAK signaling was correlated to pathways involved in glucose
homeostasis (Table 2); but whether PAK or its partners are associated in the pathogenesis of T2DM
is unknown. We identified protein-protein interactions and prospective interacting partners in the
pathogenesis of T2DM by screening PAKs 1–6 and previously identified markers of reduced beta cell
mass (Figure 1A), dysfunction (Figure 1B), and obesity and insulin resistance (Figure 1C), using the
online STRING database [4].
Thirty total PAK interacting partners were found to involve reduced Beta-cell mass (10), Beta-cell
dysfunction (10), and obesity and insulin resistance (10) (Figure 1D and Supplementary Table S1).
Signaling pathways associated with PAK interacting partners included cell cycle control, receptor
tyrosine kinases (RTK), G-proteins, and Wnt signaling (Figure 1E). Reduction in Beta-cell mass was
exclusively linked to eight-interacting partners involving cell cycle control. Beta-cell dysfunction was
found to be associated with four-interacting partners linked to Wnt signaling, and six-interacting
partners involving RTKs were associated with obesity/insulin resistance (Figure 1E). G-protein
signaling involved two-interacting partners involved in reduced Beta-cell mass, five-partners in
Beta-cell dysfunction, and four-partners in obesity/insulin resistance (Figure 1E). These data suggest
PAK interacting partners are associated with, and potentially utilize, the cell cycle, Wnt, RTK, and
G-protein signaling in the pathogenesis of T2DM.
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Figure 1. (A–E) PAK interacting partners are associated with pathogenesis of T2DM. PAK interacting 
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cell mass, (B) beta-cell dysfunction, and (C) obesity/insulin resistance. (D) Novel PAK interacting 
partners involved in reduced beta-cell mass, beta cell dysfunction, and obesity/insulin resistance are 
displayed and color coded based on their involvement in the cell cycle (blue); G-proteins (green); 
receptor tyrosine kinase (red); and Wnt signaling (purple). (E) Bar graphs indicate the number of 
interacting partners involved in pathway associated with pathogenesis of T2DM. Reduced beta cell 
mass is associated with the cell cycle, beta cell dysfunction is associated with Wnt signaling, and 
obesity/insulin resistance is associated with receptor tyrosine kinases. G-proteins are associated with 
all three pathways leading to T2DM. 
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to T2DM.
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3.3. Upstream and Downstream PAK Signaling Pathways Are Utilized by Anti-Diabetic Drugs Pioglitazone
and Metformin
We found that PAK interacting partners were correlated to the pathogenesis of T2DM. However,
the role of PAK signaling in T2DM remained elusive. We surveyed this by analyzing the effect of
anti-diabetic drugs metformin (met), glyburide (gly), and glitazones (glit) on PAK signaling pathways
(Table 4). Overall, glit and met each altered ten PAK signaling pathways, whereas gly altered three
(Figure 2A). Further analysis revealed all three anti-diabetic drugs altered pathways upstream and
downstream of PAK (Figure 2B). Glit exerted the most profound effect on downstream PAK signaling
pathways (mean: glit = 9 vs. met = 7; ANOVA, 95% CI: 0.31 to 3.2, p = 0.01) and (mean: glit = 9 vs.
gly = 3; ANOVA, 95% CI: 5.3096 to 8.1904, p = 0.001). Met altered more pathways upstream of PAK
(mean: met = 5 vs. gly = 1; ANOVA, 95% CI = −5.4 to −2.6, p = 0.001) and (mean: met = 5 vs. glit = 3;
ANOVA, 95% CI = −2.6904 to 0.1904, p = 0.11) (Figure 2B).
Malignant PAK signaling is involved in disease pathogenesis. To further understand the role in
which met, gly, and glit interfere with PAK signaling in T2DM, we asked if any of these drugs activate
or inhibit inflammatory, proliferative, survival, or angiogenic pathways upstream and downstream
of PAK (Figure 2C–F). Differential pathway analysis revealed met and glit consistently altered more
pathways than gly (Figure 2C–F). Glit inhibited more pathways downstream of PAK than met in
(inflammation: glit = 7 vs. met = 4), (proliferation: glit = 8 vs. met = 4), (survival: glit = 8 vs. met =
4), (angiogenesis: glit = 8 vs. met = 4) (Figure 2C–F). However, met activated more pathways than
glit, which are exaggerated upstream of PAK and involved in inflammation (met = 4 vs. glit = 2),
proliferation (met = 2 vs. glit = 0), survival (met = 3 vs. glit = 1), and angiogenesis (met = 3 vs. glit = 1)
(Figure 2C–F). These data suggest that anti-diabetic drugs might alter PAK signaling. Metformin may
activate pathways upstream and glitazones potentially inhibit pathways downstream of PAK.
Table 4. PAK-signaling pathways are utilized by anti-diabetic drugs. The effect of anti-diabetic drugs
metformin, glyburide, and pioglitazone on PAK signaling pathways as reported by the literature.
Arrows indicate the effect of drug on PAK signaling pathway up (increases); down (decreases);
up/down (both).
PAK Signaling Pathways Utilized by Anti-diabetic Drugs
Pathway Metformin Glyburide Glitazone Citation
AMPK ↑ - ↑ [44,45]
MAPK-p38/JNK ↑ ↑ ↓ [46–49]
MAPK-ERK ↓ - ↑↓ [47,50]
mTOR ↓ - ↓ [51–53]
NF-kB ↓ - ↓ [14,38,54,55]
p-PAK1 ↑ - - [44]
PI3K/AKT ↑ ↓ ↓ [37,48]
PPAR-γ - - ↑ [27]
RAC1/CDC42 ↑ - - [47]
RAS ↓ - - [51]
ROS - ↑ ↓ [56]
VEGF ↑↓ - ↑↓ [57,58]
Wnt/ B-catenin - - ↓ [59,60]
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Pie graph indicates total number of PAK signaling pathways utilized by metformin, glyburide, or 
glitazone. (B) Total number of pathways utilized by anti-diabetic drugs upstream or downstream of 
PAK. Note that total number of pathways in (A,B) are not equal as pathways interfered by drug may 
involve targets both up and downstream PAK. All bar graphs indicate the number of PAK signaling 
pathways involved in inflammation (C), proliferation (D), survival (E), and angiogenesis (F) upstream 
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Figure 2. (A–F) Anti-diabetic drugs utilize upstream and downstream PAK signaling pathways. (A)
Pie graph indicates total number of PAK signaling pathways utilized by metformin, glyburide, or
glitazone. (B) Total number of pathways utilized by anti-diabetic drugs upstream or downstream
of PAK. Note that total number of pathways in (A,B) are not equal as pathways interfered by drug
may involve targets both up and downstream PAK. All bar graphs indicate the number of PAK
signaling pathways involved in inflammation (C), proliferation (D), survival (E), and angiogenesis (F)
upstream or downstream of PAK, which are either activated or inhibited by anti-diabetic drugs. See
text for statistics.
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3.4. Pioglitazone and Metformin Have Therapeutic Limitations in Cancer Patients with PAK Overexpression
Previous clinical trials have attempted to establish whether met and pioglitazone (pio)
therapeutically have chemopreventive activity in humans, but the results remain highly ambiguous.
We showed that met and pio altered the pathways both upstream and downstream of PAK, and asked
whether the chemopreventive nature of these drugs was found in diseases with PAK overexpression.
To investigate this, we analyzed clinical studies in diseases known to overexpress PAK in which met or
pio treatment was tested (Table 5).
Initially, we screened hundreds of studies for diseases with PAK overexpression and either met or
pio treatment. We found one observational-prospective cohort and six interventional studies (three
single arm and three randomized double blind) with these criteria (Table 5 and Figure 3A).
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Table 5. Clinical studies using pioglitazone or metformin in diseases with PAK overexpression. Overview of clinical studies analyzed for their effect of anti-diabetic
drug pioglitazone (pio) or metformin (met) on PAK signaling pathways in diseases known to overexpress PAK.
Summary of Clinical Study Designs
Study Type Design Condition Intervention
Primary
Outcome
Measure
Number of Patients Treatment
(tx); Control (con) Duration Identifier
Observational Prospective cohort DiabetesBladder Ca Pioglitazone
Incident
Diagnoses
Tx: 34,181
Con: 158,918 10 years NCT01637935
Interventional Single group;prevention
Head/Neck Ca;
Oral Leukoplakia Pioglitazone Overall response
Tx: 21
Con: 0 12 weeks NCT00099021
Interventional Randomized; doubleblind; treatment Oral Leukoplakia Pioglitazone Overall response
Tx: 27
Con: 25 24 weeks NCT00951379
Interventional Single group;Treatment Non Small cell lung Ca Pioglitazone
% change Ki67
IHC
Tx: 6
Con: 0 14–42 days NCT01342770
Interventional Randomized; doubleblind; treatment
Prostate
adenocarcinoma Metformin
% change Ki67
IHC
Tx: 10
Con: 10 4–12 weeks NCT01433913
Interventional
Randomized; double
blind; prevention Barrett Esophagus;Esophageal Ca Metformin
% change pS6K1
IHC
Tx: 38
Con: 36 3 months NCT01447927
Interventional Single group;prevention
Adenomatous polyp;
CRC;
obesity
Metformin % changeS6-serine235
Tx: 45
Con: 0 12 weeks NCT01312467
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We investigated the effect of anti-diabetic therapy in patients with PAK over-expression by
calculating an overall clinical response rate (OCRR), which was defined as the total number of patients
who had≥50% decrease in the sum of all their lesions post-treatment. The OCRR in pio-treated patients
was 53% (Figure 3B); 28/53 patients responded and 25/53 did not. The corresponding data for met
were unavailable. To further evaluate patient outcome, we calculated the number of serious or other
adverse events after pio and met treatment (Figure 3B). Comparison of pio and met treatment revealed
a higher percentage of serious (pio: 3/53 = 5.7% vs. met: 3/91 = 3.3% chi-squared, p > 0.05) and
other (pio: 42/53 = 79% vs. met: 68/91 = 74.7% chi-squared, p > 0.05) adverse events upon treatment
with pio (Figure 3B). Additionally, in comparison to patients treated with met, a fewer percentage of
pio-treated patients were without adverse effects (pio: 11/53 = 21% vs. met: 25/91 = 27.4%) (Figure 3B).
Pioglitazone associated events included edema (15%), oral pain (13%), and hypertension (7.5%), while
those associated with metformin were gastrointestinal symptoms like constipation (7%), diarrhea
(23%), and nausea (13%). These data suggest that patients with tumors, which are known to have
PAK overexpression, may have a good clinical response to pio; and both pio and met treatment, are
associated with a high rate of mostly mild adverse events.
3.5. Pioglitazone and Metformin Alter Biomarkers Downstream of PAK in Human Disease
We correlated how patients which had diseases overexpressing PAK responded to pio, however
it was unclear whether pio or met actually interfered with PAK signaling. We therefore analyzed
biomarkers downstream of the PAK signaling pathway involved in apoptosis, cell cycle, PI3K/mTOR,
and PPARγ (Table 6).
Table 6. Pioglitazone and metformin alter biomarkers downstream of PAK in human disease. Clinical
trials, which utilized pio or met in diseases with PAK overexpression, were analyzed for their
immunohistochemistry data. Biomarkers: apoptosis (BCL2, MUC1), cell cycle control (CyclinD1,
Ki67, P21), PI3K/mTOR (PS6K1, PS6Ser235), and PPARγ. Symbols indicate (+) treatment or (-) not
available. (up or down arrow; 0) indicates percent increase or decrease in expression analyzed via IHC.
0 (no change); 1 arrow (>1% change): 2 arrows (>10% change); 3 arrows (>20% change); 4 arrows (>50%
change).
Biomarker Analysis in Cancer Patients Treated with Pioglitazone or Metformin
Disease
Drug Marker analyzed via immunohistochemistry (IHC)
Study ID
Apoptosis Cell cycle control PI3K/mTOR PPARy
pi
og
lit
az
on
e
m
et
fo
rm
in
BC
L2
M
U
C
1
C
yc
lin
D
1
K
i6
7
P2
1
PS
6K
1
PS
6s
er
23
5
To
ta
l
N
uc
le
ar
C
yt
op
la
sm
Oral
leukoplakia + -
↓
↓ -
↓
↓ ↓ ↑ - - -
↓
↓
↓
↑ NCT00951379
Non-small
cell lung Ca + - - 0
↓
↓
↓
↓
↓
↓ ↓ - -
↑
↑
↑
↑
- - NCT01342770
Prostate Ca - + - - - ↑↑ - - - - - -
NCT0143
3913
Esophageal
Ca
- + - - - - - ↑ - - - - NCT0144
7927
Colon Ca - + - - - - - - 0 - - - NCT0131
2467
We calculated the percent change in biomarker expression in pio and met treated patients to
visualize the molecular effect on PAK signaling (Figure 4). Molecular analysis revealed that pio
treatment decreased expression levels of multiple biomarkers including, apoptotic marker BCL2, and
cell cycle markers CyclinD1 and Ki67, respectively. Pio treatment increased total and cytoplasmic
PPARγ levels by 50% and 8%, however it decreased nuclear expression by 32% (Figure 4). Met
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treatment resulted in an increase in cell cycle biomarker Ki67, and did not alter expression levels
of PI3K/mTOR markers PS6K1 or PS65Ser235 (Figure 4). Further analysis showed pio inhibited
biomarkers involved in cell survival [mean: −12± 15; n = 6], whereas met stimulated similar pathways
[mean: 12.5 ± 10.6; n = 3] (p = 0.042; independent samples t-test).
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Figure 4. Pioglitazone and metformin alter biomarkers downstream of PAK in human disease. Bar
graphs are data represe ting expression of biomarkers calculated by IHC in patients treated with (+ or
-) pio [NCT00951379 (n = 25), NCT01342770 (n = 5)] or met [NCT01433913 (n = 8), NCT01447927 (n =
36), NCT01312467 (n = 32)]. See text for statistical a alysis.
4. Discussion
Type 2 d abetes is a major cause of disability and death in the elderly worldwide, and in addition
to its multiple disease specific complications, it also carries an increased cancer risk, such as colon
cancer [2]. P-21 activated kinases are serine-threonine kinases, which influence multiple cell functions
from normal cell signaling to cancer [61]. Physiological PAK signaling is regulated and implicated
in the maintenance of cellular homeostasis, however, as the extracellular microenvironment or PAK
expression in disease changes, physiological signaling becomes pathological (Figure 5). Here, we
reviewed physiological PAK signaling and found it is highly correlated with glucose homeostasis,
although PAKs role in the pathogenesis of T2DM, and cancer in diabetes patients, is largely unknown.
PAK overexpression drives malignant diseases such as cancer. However, in diabetes a different
expression pattern has been observed by Ahn et al., who reported that diabetic stressors reduce PAK1
expression in islet cells, and this decline in total protein levels may contribute to beta cell dysfunction
in diabetes [30]. Here, we emphasized the importance of PAK signaling (kinase activity) versus total
protein levels, which are more involved in scaffolding and protein-protein interactions [3]. It is likely
that chronic inflammation and hyperinsulinemia associated with T2DM [2,62,63] may both lead to
pancreatic and peripheral PAK kinase activation, in addition to reduction in total PAK protein levels,
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as PAK1 activation was previously described to down regulate itself after activation [64]. Additionally,
six different PAKs have been characterized; therefore signaling from other PAKs may compensate
for reduction in PAK1 expression, which may have also contributed to the findings observed by Ahn
and colleagues. We identified novel PAK interacting partners associated with the pathogenesis of
T2DM, involving reduced beta cell mass and dysfunction, and obesity-insulin resistance (Figure 1).
Interestingly, we identified that the PAK interacting partner IQGAP1 was involved in all three pathways
(Figure 1D). IQGAP1 acts as a molecular scaffold for small Rho-GTPase activation of PAKs [65], which
further implicates the importance of PAK kinase activation in T2DM.
Geriatrics 2018, 3, x 12 of 20 
reviewed physiological PAK signaling and found it is highly correlated with glucose homeostasis, 
although PAKs role in the pathogenesis of T2DM, and cancer in diabetes patients, is largely 
unknown. 
PAK overexpression drives malignant diseases such as cancer. However, in diabetes a different 
expression pattern has been observed by Ahn et al., who reported that diabetic stressors reduce PAK1 
expression in islet cells, and this decline in total protein levels may contribute to beta cell dysfunction 
in diabetes [30]. Here, we emphasized the importance of PAK signaling (kinase activity) versus total 
protein levels, which are more involved in scaffolding and protein-protein interactions [3]. It is likely 
that chronic inflammation and hyperinsulinemia associated with T2DM [2,62,63] may both lead to 
pancreatic and peripheral PAK kinase activation, in addition to reduction in total PAK protein levels, 
as PAK1 activation was previously described to down regulate itself after activation [64]. 
Additionally, six different PAKs have been characterized; therefore signaling from other PAKs may 
compensate for reduction in PAK1 expression, which may have also contributed to the findings 
observed by Ahn and colleagues. We identified novel PAK interacting partners associated with the 
pathogenesis of T2DM, involving reduced beta cell mass and dysfunction, and obesity-insulin 
resistance (Figure 1). Interestingly, we identified that the PAK interacting partner IQGAP1 was 
involved in all three pathways (Figure 1D). IQGAP1 acts as a molecular scaffold for small Rho-
GTPase activation of PAKs [65], which further implicates the importance of PAK kinase activation in 
T2DM. 
 
Figure 5. Role of PAK signaling in response to inflammation, altered microbiota and hyperglycemia. 
Image is read from left to right. (Far left) Binding of a Wnt ligand to the Frizzled receptor disrupts 
the multi-subunit destruction complex consisting of Axin, Dvl, GSK3beta, and APC, which normally 
tags Beta-catenin to the proteasome. Here, beta-catenin is no longer degraded but moves to the 
nucleus where it binds to TCF/LEF and initiates transcription of target genes involved in cell cycle 
progression, proliferation and survival. (Low left) Ligand binding to PPARγ results in its activation 
and nuclear translocation where it then binds RXR and induces its own transcription as well as genes 
involved in glucose homeostasis and lipid transport. PPARγ directly inhibits Beta-catenin and the 
NF-κB subunit RelA. (Central) Inflammatory cytokines like TNFalpha or microbial products such as 
Figure 5. Role of PAK signaling in response to inflammation, altered microbiota and hyperglycemia.
Image is read from left to right. (Far left) Binding of a Wnt ligand to the Frizzled receptor disrupts the
multi-subunit destruction complex consisting of Axin, Dvl, GSK3beta, and APC, which normally tags
Beta-catenin to the proteasome. Here, beta-catenin is no longer degraded but moves to the nucleus
where it binds to TCF/LEF and initiates transcription of target genes involved in cell cycle progression,
proliferation and survival. (Low left) Liga d binding to PPARγ results in its activation and nuclear
translocati where it the binds RXR and induces its own transcription as well as ge es involved
in glucose homeostasis and lipid transport. PPARγ irectly inhibits Beta-catenin and the NF-κB
subunit RelA. (Central) Inflammatory cytokines like TNFalpha or mi robial products such as EspG or
lipopoly accharid s (LPS), result in PAK1 activation. PAK1 phosphorylates Beta-catenin and leads to
its stabilization and full transcriptional activation. PAK1 phosphorylates JNK and activates the IKK
complex which disrupts RelA from IkB and leading to transcription of genes involved in inflammation
and survival. Hyperglycemia results in insulin stimulation of RTKs which further activate PAK1 or
directly contribute to a PI3K/AKT/mTOR pathway. PAK1 may also directly contribute to activation of
PI3K or mTOR or vice versa. Note that activation of the mTOR1-Raptor complex leads to transcription
of PPARγ. As PPARγ levels increase they fulfill their role in the nucleus and cytoplasm. RAS is a
key component of the MAPK and PI3K pathway. MAPK-ERK signaling results in activation of JUN
and FOS (nucleus) and inhibits PPARγ (cytoplasm). (Far right) RAC1/CDC42 are small Rho-GTPases,
which also lead to PAK1 activation. PAK1 stimulates the MAPK-ERK cascade and also inhibits PPARγ.
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The initial pathogenesis of T2DM involves beta cell expansion to compensate for hyperglycemia,
which eventually may lead to reduced beta cell mass [1]. Here, PAK interacting partners involved
with reduced beta cell mass and dysfunction were specifically associated with cell cycle regulation
and Wnt signaling (Figure 1D). It is possible that in early diabetes, hyperglycemia promotes cell cycle
progression via PAK-beta-catenin signaling [19]. Over time, PAK driven proliferation and inflammation
may lead to oxidative stress and therefore contribute to beta cell dysfunction and subsequent reduction
in beta cell mass [66]. Interestingly, in oxidative stress, nuclear beta-catenin was reported to associate
with FOXO transcription factors [67], which could potentially modulate PAK expression levels [68], in
line with reports from Ahn and colleagues. Another explanation for PAK’s role here may involve an
interaction with tumor suppressor p53 (Figure 1A,D). Interestingly, activation of both p53 and MDM2,
a p53 ubiquitin ligase, was reported in T2DM [69], and a PAK–MDM2 interaction was previously
described [70]. Others provided a role for PAK upstream of p53 [71,72], thus PAK signaling in T2DM
may activate p53 directly, or indirectly via MDM2, or through a cell stress pathway, such as oxidative
stress or stress associated MAPK like p38/JNK [73], thereby inducing apoptosis, impeding cell cycle
progression, and subsequently reducing beta cell mass. Additional PAK interacting partners associated
with pathways involving obesity-insulin resistance involved targets in RTK signaling, which is likely a
consequence of multiple growth factors, and the chronic inflammatory state associated with obesity in
T2DM [1,3,62,63].
We sought to illuminate the role of PAK signaling in T2DM by analyzing the effect that three
well-known classes of anti-diabetic drugs had on PAK signaling (Figure 2). Biguanide (metformin),
sulfonylurea (glyburide), and glitazone (pioglitazone) all interfered with signaling upstream and
downstream of PAKs, and this effect was more significant with metformin (upstream) and pioglitazone
(downstream, Figure 2). Both metformin and pioglitazone mediated inflammatory, proliferative,
survival, and angiogenic pathways associated with PAKs (Table 4 and Figure 2). However, it is
important to note that even though PAK signaling appears to be modulated by these drugs, one major
limitation of our study is a lack of an experimental model to support this, therefore we can only
speculate using the evidence we found in the literature.
Considering the role of PAK signaling in the initiation of disease [61], and that activation of PAK
signaling was correlated to T2DM (Table 2), and potentially inhibited anti-diabetic drugs (Figure 2),
we asked whether metformin or pioglitazone were beneficial in patients with PAK-overexpressing
diseases including oral cancer [74], non-small cell lung cancer [75], prostate [70], esophageal cancer [76],
bladder [77], and colorectal cancer [78]. Pre-clinical studies investigating the chemopreventive effects
of these drugs seemed promising [79–81], however, results from human studies remain highly
ambiguous [82], and a more complete analysis of this data would allocate whether inhibition of
PAK signaling pathways by metformin or pioglitazone is promising for chemoprevention. We
utilized a mini-meta-analysis of several studies (Table 5) involving metformin and pioglitazone
use in cancer patients to investigate whether these treatments are potential candidates to target PAK
signaling (Figure 3). However, it is important to note our findings here are only speculation and
we cannot definitively conclude that PAK is truly altered by met or pio in these reviewed studies.
Also, modulation of PAK signaling by these agents is largely dependent on a particular cell type
and tissue context, which is lost when combining studies with different diseases. Nonetheless, our
analysis was still able to link that pioglitazone treated patients had a clinical response rate of 53% in
PAK dependent diseases (Figure 3B). It was unfortunate that data needed to calculate response rate
to metformin were not available for analysis. Both pioglitazone and metformin treatment resulted is
relatively few serious adverse events. However, the overwhelming majority of patients, nearly 80% of
pioglitazone and 75% metformin treatment patients had mild adverse events (Figure 3B). The high
number of pioglitazone associated events such as edema and hypertension were likely due to the
advanced treatment regimen used in these patients, equivalent to 45 mg/day, versus the standard care
at a dose equivalent to 15 mg/day [83]. Other studies have indicated fewer adverse events at lower
doses, equivalent to 7.5 mg/day [83]. Although gastrointestinal symptoms like constipation, diarrhea,
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and nausea are common side effects of metformin [63], so many adverse events were unexpected
and likely not attributable to dose, as patients received a standard of care equivalent of 2000 mg/day.
Given that metformin is the gold standard in treatment of T2DM [63], the frequency of adverse events
is concerning. Although not life threatening, adverse events are a serious therapeutic limitation and
concern for future chemopreventive studies, as long-term patient compliance will dramatically decline
if quality of life is decreased by therapy. In addition to our analysis, ten-year treatment of pioglitazone
in diabetic patients was associated with increased prostate and pancreatic cancer risk [82], making its
long-term use in chemoprevention questionable.
We asked whether PAK signaling was even affected in these patients by pioglitazone or metformin
at the molecular level (Table 6 and Figure 4), and found that pioglitazone but not metformin decreased
PAK signaling pathways. This data was in line with our analysis of signaling pathways affected by
these drugs (Table 4), in that metformin induced signaling upstream of PAKs while pioglitazone rather
reduced downstream signaling (Figure 2). Here pioglitazone reduced markers of proliferation and
survival, including cyclinD1 and Ki67, while metformin had the opposite effect. Long-term treatment
with metformin in diabetic patients may therefore induce, not inhibit, long-term cancer risk, however
future studies would need to investigate this further. However, the recent work of Bradley and others
show metformin may have long-term chemopreventive effects in preventing colorectal cancer in male
diabetic patients [84]. Due to our small sample size in this study we were unable to divide or based
on gender or colon cancer, which may have masked similar findings. Also, recent reports from other
groups have shown that metformin exerts chemopreventive effects via stimulation of an AMPK-TET-2
tumor suppressor pathway [85], which to our knowledge is separate from PAK signaling pathways
discussed in this review.
Considering our clinical and molecular analysis of PAK biomarkers in pioglitazone treated
patients, future studies should investigate the long term side effects associated with its treatment and
whether PAK signaling in disease can be impeded early on, to block malignant transformation [61].
Although PAK signaling appears to promote malignant disease, whether inhibition of PAK will
exacerbate diabetes in these patients is of serious concern. Each case will ultimately need to be
analyzed on a risk-reward basis, and patients with both diabetes and increased cancer risk such as
(BRCA/Lynch Syndrome/FAP) would be more favorable candidates for long-term studies with these
potentially chemopreventive agents.
This was the first study to provide a mechanistic explanation of how anti-diabetics may target
PAK signaling for their potential use for chemoprevention in patients with T2DM, albeit our signaling
pathway analysis included multiple pre-clinical studies, which were not of high significance. Ideally, a
thorough signaling pathway analysis should use PAK1 and p-PAK1 as biomarkers in multiple human
studies, however this data was unavailable for analysis due to the limitations of the current literature
in regard to our highly specific question. Considering the few patients analyzed here, the accuracy
of this data is supported by its correlation between literature reports (Table 4 and Figure 2) and our
analysis of PAK signaling pathways from human studies (Table 6 and Figure 4). Future studies with
more patients and additional readouts of known PAK targets would provide a more clear analysis of
whether chemoprevention in diabetes with pioglitazone is feasible long term.
4.1. Future Directions
Although not associated with diabetes, other studies of chemoprevention have shown that
anti-inflammatory drugs like aspirin in colorectal cancer and mesalamine in colitis associated cancer
reduce cancer-associated risk [86,87]. Mesalamine, the first line treatment for chronic inflammation
in ulcerative colitis [88], was recently established as a PAK1 inhibitor [17], and others have shown it
is a PPARγ ligand [89]. Both of these mechanisms are in line with glitazones [14]. Therefore, future
directions in chemoprevention in diabetes should analyze PAK expression/phosphorylation upon
glitazone treatment and see if the effects are similar to those of mesalamine in impeding chronic
inflammation in colitis associated colon cancer.
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4.2. Concluding Remarks
Anti-diabetics like pioglitazone or metformin should be utilized as a platform for further
understanding the role of PAKs as a chemopreventive target in diabetes. However, before this is
possible, future studies must standardize doses specific to the associated disease in order to modulate
PAK signaling appropriately and minimize adverse effects. Ideal chemoprevention, like mesalamine,
will block inflammation and impede aberrant PAK signaling without altering cellular homeostasis.
Supplementary Materials: The following are available online, Figure S1: Role of signaling pathways upstream
and downstream of p-21 activated kinases. Figure S2: Diverse roles of PAKs in glucose homeostasis. Figure S3:
PAK signaling in disease. Table S1: The pathophysiology of PAK interacting partners in T2DM.
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